Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exercise facilitates post-stroke recovery through mitigation of neuronal hyperexcitability via interleukin-10 signaling.

Nature communications·2025

Same author

Obesity and sexual health: focus on postmenopausal women.

Climacteric : the journal of the International Menopause Society·2024

Same author

Omics sciences and precision medicine in testicular cancer.

La Clinica terapeutica·2023

Same author

Omics sciences and precision medicine in prostate cancer.

La Clinica terapeutica·2023

Same author

Correction: Smoking and diabetes: dangerous liaisons and confusing relationships.

Diabetology & metabolic syndrome·2023

Same author

Testicular volume in 268 children and adolescents followed-up for childhood obesity-a retrospective cross-sectional study.

European journal of endocrinology·2023

Search research articles

Related Experiment Video

Updated: May 31, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after

S La Vignera¹, R A Condorelli, E Vicari

¹Section of Endocrinology, Andrology and Internal Medicine, Master in Andrological, Human Reproduction and Biotechnology Sciences, Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy. sandrolavignera@email.it

International Journal of Impotence Research

|June 17, 2011

Summary

Tadalafil treatment reduced endothelial damage markers in men with erectile dysfunction. However, these positive effects on endothelial function disappeared six months after discontinuing the medication.

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Related Experiment Videos

Last Updated: May 31, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Area of Science:

Cardiovascular Medicine
Urology
Endothelial Biology

Background:

Phosphodiesterase V inhibitors are known to improve endothelial dysfunction in erectile dysfunction (ED).
Limited research exists on the duration of endothelial effects after discontinuing these medications.

Purpose of the Study:

To evaluate serum concentrations of apoptotic endothelial microparticles (EMPa) as a marker of endothelial damage.
To assess the persistence of tadalafil's endothelial benefits after discontinuation in patients with arterial ED.

Main Methods:

50 patients with arterial ED received tadalafil 5 mg daily for 90 days.
Clinical (IIEF-5), instrumental (Doppler), and flow-cytometric (serum EMPa) analyses were performed at baseline, 1 week, 3 months, and 6 months post-discontinuation.
EMPa were defined as CD45(neg)/CD144(pos)/annexinV(pos) events.

Main Results:

Patients with arterial ED had higher baseline serum EMPa concentrations than healthy controls.
Tadalafil administration significantly reduced EMPa levels at 1 week post-treatment.
This reduction was maintained, albeit diminished, at 3 months but completely lost by 6 months post-discontinuation.

Conclusions:

Tadalafil administration effectively decreases endothelial damage markers in patients with arterial ED.
The beneficial effects of tadalafil on endothelial dysfunction are temporary and resolve within 6 months of cessation.